[SCHEDULE 13G] MediWound Ltd. Passive Investment Disclosure (>5%)

Rhea-AI Filing Summary

MEDIWOUND LTD reported a Schedule 13G filing showing T. Rowe Price Associates, Inc. holds 5.5% of common stock, amounting to 709,847 shares. The filer discloses sole voting power of 707,170 shares and sole dispositive power of 709,847 shares. The filing includes a statement denying beneficial ownership. Signature date: 05/15/2026.

Insights

Institutional Ownership Analyst

T. Rowe Price reports a 5.5% position in MEDIWOUND (common stock).

The filing quantifies holdings as 709,847 shares with sole voting power of 707,170 and sole dispositive power of 709,847. These figures describe the holder's reported capacities to vote and dispose of shares as stated.

The filing also includes an explicit denial of beneficial ownership by the filer; governance implications depend on the underlying ownership structure and are not detailed here. Subsequent disclosures or agreement texts would clarify actual beneficial ownership and voting influence.

Regulatory Compliance Specialist

The Schedule 13G disclosure is a passive reporting disclosure under beneficial-ownership rules.

As a Schedule 13G, this filing indicates a reported position at the 5.5% threshold. The statement denying beneficial ownership is a formal qualifier that affects attribution and should be reviewed against underlying account agreements.

Timing and any change-of-control intent are not stated; future amendments would show updates if the position changes or the filer asserts beneficial ownership.

Key Figures

Shares reported: 709,847 shares Percent of class: 5.5% Sole voting power: 707,170 shares +1 more

4 metrics

Shares reported 709,847 shares Amount beneficially owned as reported on Schedule 13G

Percent of class 5.5% Percent of common stock represented by 709,847 shares

Sole voting power 707,170 shares Shares as to which filer has sole power to vote

Sole dispositive power 709,847 shares Shares as to which filer has sole power to dispose

Key Terms

Schedule 13G, Beneficial ownership, Sole dispositive power

3 terms

Schedule 13G regulatory

"Schedule 13G filing showing ownership disclosure"

A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.

Beneficial ownership regulatory

"T. Rowe Price expressly denies that it is the beneficial owner"

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

Sole dispositive power regulatory

"Sole power to dispose or to direct the disposition of: 709,847"

Sole dispositive power is the exclusive legal authority to decide what happens to a security — for example, whether to sell, transfer, or retain shares — without needing anyone else’s permission. Investors care because it signals who truly controls the economic outcome of an investment: like holding the only key to a safe, the holder can realize gains or losses and may trigger regulatory reporting, insider rules, or influence over corporate ownership.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

MEDIWOUND LTD

(Name of Issuer)

COMMON STOCK

(Title of Class of Securities)

M68830112

(CUSIP Number)

03/31/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): M68830112

1

Names of Reporting Persons

T. Rowe Price Associates, Inc.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

MARYLAND

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 707,170.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 709,847.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

709,847.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.5 %

12

Type of Reporting Person (See Instructions)

IA

SCHEDULE 13G

Item 1.
(a)	Name of issuer: MEDIWOUND LTD
(b)	Address of issuer's principal executive offices: 42 HAYARKON STREET, YAVNE, L3, 8122745
Item 2.
(a)	Name of person filing: T. Rowe Price Associates, Inc.
(b)	Address or principal business office or, if none, residence: 1307 Point Street, Baltimore, MD 21231
(c)	Citizenship: Maryland
(d)	Title of class of securities: COMMON STOCK
(e)	CUSIP Number(s): M68830112
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 709847
(b)	Percent of class: 5.5 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 707170
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 709847
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. T. Rowe Price Associates, Inc. hereby declares and affirms that the filing of Schedule 13G shall not be construed as an admission that Price Associates is the beneficial owner of the securities referred to, which beneficial ownership is expressly denied.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

T. Rowe Price Associates, Inc.

Signature:	Ellen York
Name/Title:	Vice President
Date:	05/15/2026

FAQ

What stake does T. Rowe Price report in MDWD?

T. Rowe Price reports 709,847 shares, equal to 5.5% of MEDIWOUND's common stock. The filing lists sole voting power of 707,170 shares and sole dispositive power of 709,847 shares, per the Schedule 13G disclosure.

Does the Schedule 13G say T. Rowe Price is the beneficial owner of MDWD shares?

No. The filing includes an explicit statement in which T. Rowe Price denies beneficial ownership. That qualifier means the filer asserts it is reporting under its capacity but is not claiming beneficial ownership in this filing.

When was the Schedule 13G for MDWD signed?

The Schedule 13G was signed by Ellen York, Vice President, on 05/15/2026. The cover data shows an ownership reporting date tied to the filing and the signature date recorded on the form.

What voting and dispositive powers are reported by T. Rowe Price for MDWD?

The filing reports sole voting power over 707,170 shares and sole dispositive power over 709,847 shares. Shared voting and dispositive powers are reported as 0 in the Schedule 13G.